The oral antiviral obeldesivir reduces viral load in high-risk outpatients with COVID but does not lower the rate of ...

Remdesivir (Veklury, Gilead) was found to reduce some COVID-19 patients' risk of hospitalization by 87% in a phase 3 trial, the drug's manufacturer announced Wednesday in a press release.

Gilead CEO Daniel O'Day discusses the FDA's emergency use authorization of remdesivir as a potential COVID-19 treatment on the White House on Friday, May 1.

Gilead also is testing remdesivir in a separate study of moderately ill coronavirus patients. No results have yet been announced from that study, which does have a comparison group.

Obeldesivir provided faster symptom relief but did not reduce hospitalization or all-cause mortality in high-risk nonhospitalized patients with COVID-19.

Gilead's anti-viral remdesivir gets FDA emergency use authorisation for treatment of COVID-19. US-based biopharmaceutical ...

Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...